Table 3 Complete cytogenetic response at 6, 12 and 18 months
Intervention | Probability of response | Response odds ratios |
|---|---|---|
(Mean, 95%CrI) | (Mean, 95%CrI) | |
CCyR at 6 months | ||
Imatinib 400 mg daily | 40.1% (Reference Category) | N/A (Reference Category) |
Dasatinib 100 mg daily | 55.3% (22.9-86.7%) | 2.98 (0.45-9.76) |
Nilotinib 300 mg twice daily | 60.7% (21.9-86.8%) | 3.06 (0.42-9.85) |
Nilotinib 400 mg twice daily | 56.8% (20.4-85.5%) | 2.77 (0.38-8.82) |
Imatinib 800 mg daily | 53.8% (35.7-71.8%) | 1.92 (0.83-3.81) |
CCyR at 12 months | ||
Imatinib 400 mg daily | 62.4% (Reference Category) | N/A (Reference Category) |
Dasatinib 100 mg daily | 77.1% (67.2-85.3%) | 2.16 (1.23-3.5) |
Nilotinib 300 mg twice daily | 77.7% (64.8-87.7%) | 2.41 (1.11-4.29) |
Nilotinib 400 mg twice daily | 75.3% (61.0-86.1%) | 2.06 (0.95-3.73) |
Imatinib 800 mg daily | 70.1% (62.1-76.9%) | 1.45 (0.99-2.01) |
CCyR at 18 months | ||
Imatinib 400 mg daily | 71.6% (Reference Category) | N/A (Reference Category) |
Dasatinib 100 mg daily | 79.1% (72.0-85.1%) | 1.55 (1.02-2.27) |
Nilotinib 300 mg twice daily | 83.1% (76.7-88.4%) | 2.01 (1.31-3.00) |
Nilotinib 400 mg twice daily | 80.0% (73.0-85.8%) | 1.63 (1.07-2.40) |
Imatinib 800 mg daily | 77.9% (71.9-83.2%) | 1.43 (1.01-1.96) |